BOCH
ARTV

Blue Owl Capital Holdings’s Artiva Biotherapeutics ARTV Stock Holding History

Blue Owl Capital Holdings’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.48M Buy
+874,542
New +$7.96M 1.28% 15

Other funds holding ARTV

Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $136M AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Blue Owl Capital Holdings's ARTV Position: Q2 2026 in Review

Blue Owl Capital Holdings opened a new position in Artiva Biotherapeutics (ARTV) in Q2 2026: 874,542 shares worth $8.48M. The stake represents 1.28% of the portfolio and ranks #15 among its holdings.

38 funds tracked by Wall St. Rank hold ARTV as of Q2 2026.

  • Blue Owl Capital Holdings held 874,542 shares of Artiva Biotherapeutics worth $8.48M as of Q2 2026.
  • Artiva Biotherapeutics was a new Blue Owl Capital Holdings position in Q2 2026.
  • Artiva Biotherapeutics made up 1.28% of Blue Owl Capital Holdings's portfolio in Q2 2026, its #15 holding.
  • 38 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q2 2026.

Based on Blue Owl Capital Holdings's 13F filing for Q2 2026, filed 11 Aug 2026.